Immuron Limited Overview
Immuron is an Australian commercial- and clinical-stage biopharmaceutical micro-cap built on a proprietary platform of orally delivered polyclonal antibodies harvested from the colostrum of dairy cows immunised against specific gut pathogens. Its economic engine today is Travelan®, an over-the-counter tablet for reducing the risk of travellers' diarrhoea, sold as a listed medicine in Australian pharmacy, a natural health product in Canada and a dietary supplement in the United States; Travelan generated essentially all of FY2026 revenue of A$7.71 million. Gross margins are attractive (64.5% in FY2026) but the business remains loss-making after sales, marketing and corporate costs. Behind the consumer franchise sit two FDA-IND-stage prescription assets — IMM-124E (travellers' diarrhoea) and IMM-529 (Clostridioides difficile infection) — which, following a February 2026 "Strategic Reset", management now intends to out-license rather than fund through Phase 3. The investment case is therefore a hybrid of a small, growing consumer-health brand and binary partnering optionality on the pipeline.
Company's own description (FY2026 Form 20-F, paraphrased)
In its FY2026 annual report on Form 20-F, Immuron describes itself as a commercial and clinical-stage biopharmaceutical company whose proprietary technology platform develops and commercialises a novel class of specifically targeted polyclonal antibodies aimed at significant unmet medical needs. It currently markets Travelan® and ProIBS® in Australia (both listed on the Australian Register of Therapeutic Goods — Travelan AUST L 106709; ProIBS AUST L 482225), Travelan in Canada as a licensed natural health product (NPN 80046016), and Travelan in the U.S. as a dietary supplement for digestive tract protection. Protectyn® (AUST L 231001), previously sold online and through practitioner clinics as an immune/digestive supplement, was cancelled and removed from the ARTG in June 2026. The company emphasises that its antibodies act within the gastrointestinal tract and do not enter the bloodstream, which it believes supports safety and tolerability.
The 20-F's liquidity section describes a "two-pronged" value-creation approach: in the short to medium term, sell and license the Travelan OTC product; beyond that, research and clinically develop products principally for travellers' diarrhoea and C. difficile infection.
Platform technology
Pregnant dairy cows are immunised with vaccines containing antigens of human enteric pathogens. The resulting hyper-immune bovine colostrum (HBC) is rich in pathogen-specific IgG. According to the company, bovine IgG survives gastric acid and resists proteolysis, remaining active in the human GI tract where it binds bacteria, blocks colonisation and neutralises toxins. IMM-124E (the active in Travelan) is generated from cows vaccinated with outer antigens of 13 human-derived enterotoxigenic E. coli (ETEC) strains; the colostrum contains antibodies against ETEC LPS, CFA-I and flagellin. IMM-529 targets three C. difficile virulence components — Toxin B, spores and surface-layer proteins of vegetative cells — and was developed with Dr Dena Lyras' group at Monash University.
Business model and revenue model
| Revenue model element | FY2026 contribution | Comment |
|---|---|---|
| Product sales (OTC consumer health) | 100% of revenue from contracts with customers (A$7.71m) | Travelan 98.6%, ProIBS 1.1%, Protectyn 0.3% |
| Licensing / royalties | 0% | Management intends to out-license IMM-124E and IMM-529; no deal signed as of October 2026 |
| Contract research / manufacturing services | First revenue received May 2026 under the DoD/HJF Campylobacter–Shigella program (amount not separately disclosed); HJF R&D grant A$339,819 booked as other income | 20-F risk factors reference "our ability to successfully expand our contract manufacturing services" |
| Subscriptions / services | — | — |
| Non-operating support | Australian R&D Tax Incentive (A$782,313 audited, FY2026) and R&D grants (HJF A$339,819) recorded in other income | Material relative to revenue; proposed May 2026 reforms may end eligibility (Section 18) |
Value-chain position
Immuron is an asset-light brand owner and IP holder. It does not own farms or factories. Hyper-immune colostrum for IMM-124E is produced by Bovogen Biologicals (Australia); finished Travelan product is made by contract manufacturers including Mayne Pharma International; IMM-529 GMP process development is with Syntro Health (FY2026 20-F risk factors). Immuron controls vaccine/antigen know-how, regulatory dossiers, brand, marketing and distribution relationships. Downstream, it sells through pharmacy wholesalers and retailers in Australia (notably Chemist Warehouse/Sigma), Amazon and online channels in the U.S., and pharmacy chains in Canada (including Jean Coutu in Québec from Q3 FY2026).
Customer types and end-markets
| Customer type | End-market | Products |
|---|---|---|
| Pharmacy wholesalers and retail chains (Australia) | Consumer travel health; digestive health/IBS | Travelan, ProIBS |
| E-commerce (Amazon U.S.) and U.S. retail | Consumer dietary supplements / travel health | Travelan |
| Canadian pharmacy chains (>1,000 doors listed in FY2025; Jean Coutu, Québec, FY2026) | Natural health products / travel health | Travelan |
| U.S. Department of Defense research bodies (NMRC, WRAIR via Henry M. Jackson Foundation) | Military force-health protection R&D | Bespoke HBC products for pre-clinical evaluation |
| Future pharma licensees (sought) | Prescription anti-infectives (TD prophylaxis; CDI) | IMM-124E, IMM-529 |
Independent characterisation
Immuron is best understood as a sub-scale consumer-health brand company carrying a legacy biotech cost structure and listing burden (dual ASX/Nasdaq). Travelan has demonstrably scaled post-COVID — revenue rose roughly tenfold from FY2022 to FY2026 — but growth decelerated sharply to 5.9% in FY2026 as the post-pandemic travel rebound normalised and Canada's pipeline-fill comparison unwound. The prescription pipeline has been de-risked regulatorily (two INDs) but not clinically for the commercial dosing regimen in a field setting: the December 2025 military field study missed its primary endpoint, albeit with a third-party product dosed off-label. The February 2026 pivot to partnering is an explicit admission that the balance sheet cannot fund Phase 3. Value therefore depends on (a) whether Travelan can sustain double-digit growth and reach EBITDA (ex-R&D) breakeven, and (b) whether IMM-529 in particular can attract a licensee on terms that matter relative to a ~US$14 million market capitalisation.
Strategy
Stated strategy themes
"Make Travelan the must-have travel essential": for consumers and retailers (FY2025 sales release, July 2025).
Strategic Reset (25 February 2026): pursue partnerships to fund progress of IMM-124E and IMM-529 rather than self-fund late-stage trials; focus internal capital on the consumer franchise. Management positioned Immuron as no longer a "concept" company, citing consistent revenue growth as a competitive moat.
EBITDA (ex-R&D) breakeven: as the near-term financial objective (AGM, 11 November 2025).
FY2027 plan (28 August 2026): invest to grow North America while maintaining Australian momentum, with quarterly milestones: Q1 continued Travelan growth; Q2 portfolio expansion; Q3 IMM-529 partnering progress; Q4 geographic expansion, improved profitability and reduced cash burn.
Initiatives in the last 24 months
| Initiative | Date | Description | Status |
|---|---|---|---|
| ProIBS in-licensing and launch | Agreement 2025; launch 24 Oct 2025 | Exclusive ANZ distribution of Calmino's AVH200-based IBS product; first portfolio extension beyond hyper-immune products | Launched; A$85k FY2026 revenue |
| Canadian channel expansion | FY2025–FY2026 | Pipeline fill into >1,000 stores; Jean Coutu (Québec) listing; in-store education and promotions | Q4 FY2026 sales up several-fold YoY |
| U.S. digital marketing | FY2025–FY2026 | Amazon optimisation, targeted messaging, social-media influencer campaigns | U.S. +13% in USD FY2026 |
| Australian brand refresh | Q4 FY2026 | New Travelan packaging and creative | Launched |
| IMM-529 IND | Submitted Oct 2025; approved Nov 2025 | Phase 2 enabling (first-episode and recurrent CDI) | Phase 2 contingent on partner |
| Partnering program | Feb 2026 onward | Out-license IMM-124E and IMM-529; Pullan Consulting engaged for IMM-529 (6 Jul 2026) | Ongoing; no deal announced |
| DoD Campylobacter/Shigella program | Dec 2025 | Produce two HBC products for pre-clinical evaluation under HJF collaborative agreement | First revenue May 2026 |
| AFRIMS testing | Dec 2025 | Test Travelan against EAEC/EPEC to inform a broader military-relevant formulation | Discussions advanced |
| Cost program | FY2026 | R&D cut 46%; G&A cut 4% | Net loss improved A$1.4–1.5m |
| Capital management | Jul–Dec 2025; Jun 2026 | ATM raises (~A$7.1m gross); unmarketable parcel buy-back | Completed |
| ESG / sustainability commitments | — | None disclosed | — |
Medium-term targets / guidance
Management guided (February 2026) that 2H FY2026 and FY2026 net sales and net profit would exceed the prior comparative periods; both were achieved. No quantitative FY2027 revenue or profit guidance has been published; the FY2027 framework is qualitative.
Products & Services
Hyper-immune Products (commercial)
Travelan® (IMM-124E, caplets)
-
Description: purified tablet of hyper-immune bovine colostrum antibodies against 13 ETEC strains plus other colostrum factors; taken with/before meals to bind diarrhoea-causing bacteria and prevent colonisation.
-
Regulatory status/claims: Australia — ARTG listed medicine AUST L 106709, indicated to reduce risk of travellers' diarrhoea and minor GI disorders, and antimicrobial; Canada — natural health product NPN 80046016 to reduce risk of TD; U.S. — dietary supplement for digestive tract protection.
-
Dosing: one to two caplets before each meal (three times daily), per the 10 December 2025 release.
-
Target customer: leisure and business travellers to high-risk (lower/middle-income) destinations; secondarily military/deployed personnel.
-
Channels: Australian pharmacy (Chemist Warehouse/Sigma and other banners), Amazon U.S., Canadian pharmacy (>1,000 doors; Jean Coutu from Q3 FY2026).
-
Launch: available in Australia since the Anadis era (Canada distribution from 2005); U.S. and Canada launches under Anastasiou-era board (2013–2024). New packaging and creative launched in Q4 FY2026 (StockWireX summary of 16 July 2026 release).
-
Pricing: not publicly disclosed in sources reviewed.
-
FY2026 revenue: A$7.607m (Australia 5.673, U.S. 1.768, Canada 0.166).
ProIBS® (in-licensed)
-
Description: CE/TGA-listed medical product containing AVH200®, derived from Aloe barbadensis Mill., which forms a hydrogel film supporting the intestinal mucosal barrier; for relief of symptoms of medically diagnosed IBS (abdominal pain, bloating, diarrhoea and/or constipation). Developer: Calmino group AB (Sweden). Calmino's usability study of 1,003 users reported 94% found it helpful (company-cited, not peer-reviewed).
-
Regulatory: ARTG AUST L 482225.
-
Rights: exclusive distribution for Australia and New Zealand.
-
Launch: officially launched in Australia 24 October 2025.
-
Target customer: adults with IBS (company cites healthdirect estimate that ~3 in 10 people are affected).
-
FY2026 revenue: A$0.085m (first partial year).
Protectyn® (discontinued)
-
Description: hyper-immune colostrum immune supplement marketed to support healthy digestive function and liver.
-
Status: cancelled and removed from ARTG June 2026.
-
Revenue: FY2023 A$0.060m; FY2024 A$0.043m; FY2025 A$0.049m; FY2026 A$0.022m.
Research and Development (clinical and pre-clinical)
| Asset | Indication | Mechanism | Stage (Oct 2026) | Key data | Commercial estimate | Strategy |
|---|---|---|---|---|---|---|
| IMM-124E (Rx Travelan) | Prevention of travellers' diarrhoea (ETEC) | Anti-ETEC polyclonal IgG (LPS, CFA-I, flagellin) | FDA IND approved Dec 2022; eligible for End-of-Phase 2 (EOP2) meeting | Otto et al. 2011 CHIM: 90.5% protection (n=30, 400mg TID); 58–83% (n=60); 2024 Phase 2 CHIM: 36.4% protective efficacy once-daily 1200mg (attack rate 37%); USU P2TD field study missed primary endpoint (third-party 600mg sachet BID) | Lumanity peak U.S. sales US$102m | Partner (Strategic Reset Feb 2026); propose TID caplet regimen at EOP2 |
| IMM-529 | C. difficile infection — treatment and prevention of recurrence, adjunct to antibiotics | Three-target HBC: Toxin B, spores, surface-layer proteins | FDA IND 32095 approved Nov 2025; Phase 2-ready | Pre-clinical: 80% prevention of primary disease (P=0.0052); 67% protection vs recurrence (P<0.01); 78.6% treatment of primary disease (P<0.0001) (Hutton et al., Sci Rep 2017) | Lumanity peak U.S. sales US$400m | Partner; Pullan Consulting engaged 6 Jul 2026 |
| DoD Campylobacter / Shigella HBC products | Military-relevant enteric infections | Two HBC products from NMRC/WRAIR-developed vaccines | Pre-clinical; first revenue May 2026 | — | — | Funded by DoD sub-award via Henry M. Jackson Foundation |
| CampETEC (NMRC) | Campylobacter + ETEC | HBC manufactured by Immuron from NMRC vaccine | Phase 2 CHIM completed 2024 | Interim 10.4% protective efficacy (n=27) | — | Collaboration; no further development disclosed |
| Travelan vs EAEC/EPEC (AFRIMS testing) | Broader E. coli coverage | Testing existing product | Discussions advanced (Dec 2025) | — | — | Could add a vaccine to IMM-124E manufacturing |
| IMM-986 | Not specified in sources | — | Pre-clinical (Yahoo Finance profile) | — | — | Status not disclosed |
Financial Narrative
All figures A$ millions unless stated; fiscal years ended 30 June. Sources: FY2023 Appendix 4E (FY2022 comparatives), FY2024 Appendix 4E (FY2023 comparatives), FY2026 Appendix 4E (FY2025 audited comparatives), FY2026 Form 20-F (FY2026 audited net loss).
Income statement
FY2026 net loss per preliminary 4E: A$3.839m; per audited 20-F: A$3.680m.
Margins and growth
Revenue CAGR FY2022–FY2026 (4 years): 78.2%. Revenue CAGR FY2023–FY2026 (3 years): 62.3%. Both are flattered by the COVID-depressed FY2022 base; the FY2026 growth rate of 5.9% is the more relevant run-rate indicator.
Commentary — P&L. The five-year arc has three phases. FY2022–FY2023 was recovery from near-zero travel: revenue of A$0.77m in FY2022 more than doubled in FY2023 as borders reopened. FY2024–FY2025 was the inflection: revenue rose 171.7% and then 48.6% on Australian pharmacy expansion (FY2024 Australian Travelan sales of A$3.7m vs A$1.1m in FY2023), U.S. Amazon traction and the Canadian pipeline fill. FY2026 was normalisation: growth slowed to 5.9% as Canada lapped its pipeline fill (-56%) and Chemist Warehouse/Sigma reduced Travelan inventories under a supply-chain efficiency program, a one-off headwind the company says it absorbed while still growing Australia 10%.
Gross margin has drifted down ~8 points from FY2023's 72.5% to 64.5%. Plausible drivers (not quantified by the company) include channel mix toward large pharmacy groups, promotional pricing in Canada, inventory provisioning effects (FY2023 benefited from a A$0.43m inventory-provision release), and the strong Australian dollar compressing U.S.-dollar sales translated to A$ (U.S. sales +13% in USD but +7% in AUD in FY2026).
The improvement in the bottom line in FY2026 is driven overwhelmingly by R&D, which fell A$1.66m (-46%) as the company stopped self-funding clinical work after the USU study read out and the Strategic Reset took effect. Selling and marketing was held flat at ~A$3.47m and G&A fell 4%. Critically, the business is still not profitable before R&D: FY2026 gross profit of A$4.98m did not cover S&M plus G&A of A$7.78m, a A$2.80m gap that was partially bridged by A$1.0–1.2m of R&D tax incentive and grant income. Management's stated target is "EBITDA (ex-R&D) breakeven" (AGM 11 November 2025; defined as EBITDA adding back R&D, less R&D tax incentive and grants).
Balance sheet
Notes: FY2023–FY2024 "lease liabilities" are the "other current/non-current liabilities" lines, which analyst judgement treats as lease liabilities. Goodwill/intangibles are taken as nil because NTA calculations exclude only right-of-use assets. FY2026 balance sheet is 4E basis; the audited 20-F implies a higher R&D tax receivable (A$782,313 vs A$623,613) and therefore slightly higher assets and equity. FY2025 NTA as restated in FY2026 4E (3.45c) vs 3.39c originally reported.
Commentary — balance sheet. Immuron is debt-free and has never relied on borrowings. Equity has been eroded from A$23.2m (FY2022) to A$8.1m (FY2025) by cumulative losses before the FY2026 ATM raises rebuilt it to A$11.0m. The liquidity low point was 30 June 2025, when cash plus term deposits stood at A$5.87m against an annual operating outflow of A$6.1m — this explains the aggressive ATM usage in July–December 2025. The share count rose 38% in FY2026 (233.96m to 322.85m), the single largest dilution event in the company's recent history. Inventory of A$2.27m equals roughly 300 days of FY2026 COGS, which is high and warrants monitoring for obsolescence given colostrum shelf-life.
Cash flow
Commentary — cash flow. Operating burn roughly halved in FY2026 to A$3.26m as R&D was cut and DoD grant funding (MTEC in FY2023–FY2024, HJF in FY2026) offset some program costs. Note the FY2023–FY2024 burn was cushioned by A$3.1m and A$1.9m of MTEC grant receipts that have now ended. FY2026 FCF of -A$3.26m against A$9.0m of cash implies roughly 2.5–3 years of runway at the FY2026 rate, consistent with the Emerging Growth Research note (March 2026) that capital provides runway "into 2027" at then-expected spend; however, management has flagged FY2027 investment in North American growth, which could lift burn before the targeted Q4 FY2027 reduction. The FY2026 buy-back (A$0.12m) was an unmarketable-parcel clean-up, not a capital-return program.
Ratios
Net debt/EBITDA and interest coverage are not meaningful (net cash; negative EBIT; no interest-bearing debt). ROIC is not meaningful given negative NOPAT and an invested-capital base dominated by cash. A full cash-conversion cycle is not computed because trade payables include operating-expense creditors and cannot be isolated against COGS. FY2026 ROE/ROA use audited net loss and 4E balance sheet.
Ratio commentary. Return metrics are deeply negative but improving; asset turnover has risen from 0.26x to 0.67x as revenue scaled against a shrinking asset base. Inventory days have improved from >500 to ~270 but remain elevated for a consumer product, reflecting long colostrum production lead-times and batch economics.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products / activities |
|---|---|---|
Hyper-immune Products | Commercial OTC portfolio and related inventory, marketing, distribution | Travelan (AU, US, CA), ProIBS (AU; in-licensed, not hyper-immune technology but reported within this revenue line), Protectyn (discontinued June 2026) |
Research and Development | Clinical and pre-clinical programs; government/DoD-funded research | IMM-124E (TD Rx), IMM-529 (CDI), DoD Campylobacter/Shigella HBC program, platform research |
Revenue by Segment
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Hyper-immune Products revenue (AUD Mn) | 4.903 | 7.287 | 7.714 |
Research and Development external revenue (AUD Mn) | 0 | 0 | 0 |
Total revenue from contracts with customers (AUD Mn) | 4.903 | 7.287 | 7.714 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Segment metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Hyper-immune Products revenue YoY growth (%) | 171.7 | 48.6 | 5.9 |
Hyper-immune Products share of total revenue (%) | 100 | 100 | 100 |
Hyper-immune Products gross margin (%) | 68.1 | 65.4 | 64.5 |
Hyper-immune Products segment profit (AUD Mn) | — | 1.35 | — |
R&D segment expense (AUD Mn, consolidated R&D line) | 5.375 | 3.597 | 1.933 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 0.765 | 1.805 | 4.903 | 7.287 | 7.714 |
Revenue YoY growth (%) | — | 135.8 | 171.7 | 48.6 | 5.9 |
Cost of goods sold (AUD Mn) | — | 0.496 | 1.566 | 2.522 | 2.739 |
Gross profit (AUD Mn) | — | 1.309 | 3.337 | 4.765 | 4.975 |
Other income incl. R&D tax incentive and grants (AUD Mn, 4E basis) | — | 2.591 | 3.408 | 1.412 | 1.011 |
General and administrative expenses (AUD Mn) | — | 4.221 | 4.556 | 4.484 | 4.306 |
Research and development expenses (AUD Mn) | — | 2.592 | 5.375 | 3.597 | 1.933 |
Selling and marketing expenses (AUD Mn) | — | 0.927 | 2.030 | 3.452 | 3.472 |
Operating loss (AUD Mn, 4E basis) | -2.870 | -3.569 | -5.801 | -5.345 | -4.009 |
EBITDA (AUD Mn, operating loss plus disclosed depreciation) | — | -3.520 | -5.755 | — | — |
Share of loss/impairment of associate Ateria (AUD Mn) | 0 | -0.324 | -1.456 | 0 | 0 |
Pre-tax loss (AUD Mn, 4E basis) | -2.854 | -3.787 | -6.937 | -5.216 | -3.839 |
Income tax (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Net loss (AUD Mn, audited where available) | -2.854 | -3.787 | -6.937 | -5.216 | -3.680 |
Basic and diluted EPS (A cents, 4E basis) | -1.25 | -1.66 | -3.04 | -2.26 | -1.29 |
Dividends per share (A cents) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | — | 72.5 | 68.1 | 65.4 | 64.5 |
Operating margin (%, 4E basis) | -375.0 | -197.8 | -118.3 | -73.3 | -52.0 |
EBITDA margin (%) | — | -195.0 | -117.4 | — | — |
Net margin (%, audited where available) | -373.0 | -209.8 | -141.5 | -71.6 | -47.7 |
R&D as % of revenue (%) | — | 143.6 | 109.6 | 49.4 | 25.1 |
Selling and marketing as % of revenue (%) | — | 51.4 | 41.4 | 47.4 | 45.0 |
G&A as % of revenue (%) | — | 233.9 | 92.9 | 61.5 | 55.8 |
Balance Sheet and Share Count (millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | — | 21.988 | 15.550 | 10.130 | 12.993 |
Cash and cash equivalents (AUD Mn) | 22.110 | 17.160 | 11.657 | 2.831 | 9.018 |
Term deposits classified as other current assets (AUD Mn) | — | 0 | 0 | 3.036 | 0 |
Cash plus term deposits (AUD Mn) | 22.110 | 17.160 | 11.657 | 5.867 | 9.018 |
Borrowings short-term (AUD Mn) | — | 0 | 0 | 0 | 0 |
Borrowings long-term (AUD Mn) | — | 0 | 0 | 0 | 0 |
Lease liabilities total (AUD Mn) | — | 0.189 | 0.173 | 0.117 | 0.190 |
Net debt incl. leases, negative = net cash (AUD Mn) | — | -16.971 | -11.484 | -5.750 | -8.828 |
Total equity (AUD Mn) | 23.177 | 19.617 | 12.709 | 8.069 | 11.006 |
Goodwill and intangibles (AUD Mn) | — | 0 | 0 | 0 | 0 |
Inventories current plus non-current (AUD Mn) | — | 2.060 | 2.254 | 1.773 | 2.274 |
Trade and other receivables (AUD Mn) | 0.663 | 0.417 | 1.388 | 1.926 | 1.250 |
Total current assets (AUD Mn) | — | 20.409 | 14.726 | 10.015 | 12.800 |
Total current liabilities (AUD Mn) | — | 2.219 | 2.699 | 1.966 | 1.786 |
Working capital (AUD Mn) | — | 18.190 | 12.027 | 8.049 | 11.015 |
Accumulated losses (AUD Mn) | 68.425 | 72.055 | 78.968 | 82.443 | 85.129 |
Ordinary shares outstanding (millions) | 227.798 | 227.798 | 227.998 | 233.959 | 322.848 |
Net tangible assets per share (A cents) | — | 8.53 | 5.51 | 3.45 | 3.35 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers (AUD Mn) | — | 1.913 | 4.734 | 7.593 | 8.480 |
R&D tax incentive refund received (AUD Mn) | — | 0.252 | 0.395 | 0.768 | 1.111 |
Grants received (AUD Mn) | — | 3.082 | 1.901 | 0.275 | 0.340 |
Operating cash flow (AUD Mn) | -3.148 | -2.595 | -5.880 | -6.137 | -3.260 |
Capital expenditure (AUD Mn, outflow) | — | 0.008 | 0.000 | 0 | 0.005 |
Free cash flow (AUD Mn) | — | -2.603 | -5.880 | -6.137 | -3.264 |
Investment in associate Ateria (AUD Mn, outflow) | 0 | 2.730 | 0 | 0 | 0 |
Proceeds from share issues gross (AUD Mn) | — | 0 | 0.024 | 0.397 | 7.149 |
Share issue transaction costs (AUD Mn) | — | 0 | 0 | 0.124 | 0.493 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buy-backs (AUD Mn) | 0 | 0 | 0 | 0 | 0.122 |
Net change in cash (AUD Mn) | — | -5.261 | -5.552 | -8.838 | 6.456 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Return on average equity (%) | -17.7 | -42.9 | -50.2 | -38.6 |
Return on average assets (%) | — | -37.0 | -40.6 | -31.8 |
Current ratio (x) | 9.20 | 5.46 | 5.09 | 7.17 |
Debt to equity, borrowings only (x) | 0 | 0 | 0 | 0 |
Lease liabilities to equity (x) | 0.01 | 0.01 | 0.01 | 0.02 |
Asset turnover (x) | — | 0.26 | 0.57 | 0.67 |
Days inventory outstanding (days, average inventory / COGS) | — | 503 | 291 | 270 |
Days sales outstanding (days, year-end trade receivables / revenue) | 3.8 | 44.0 | 39.6 | 29.7 |
Revenue by Region
| Product and geography | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Travelan Australia (AUD Mn) | 1.101 | 3.703 | 5.201 | 5.673 |
Travelan United States (AUD Mn) | 0.643 | 1.076 | 1.658 | 1.768 |
Travelan Canada (AUD Mn) | 0.001 | 0.081 | 0.379 | 0.166 |
Protectyn Australia (AUD Mn) | 0.060 | 0.043 | 0.049 | 0.022 |
ProIBS Australia (AUD Mn) | 0 | 0 | 0 | 0.085 |
Total (AUD Mn) | 1.805 | 4.903 | 7.287 | 7.714 |
Revenue by Region by Region
| Region | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Australia (APAC) revenue (AUD Mn) | 1.161 | 3.746 | 5.250 | 5.780 |
United States revenue (AUD Mn) | 0.643 | 1.076 | 1.658 | 1.768 |
Canada revenue (AUD Mn) | 0.001 | 0.081 | 0.379 | 0.166 |
North America total revenue (AUD Mn) | 0.644 | 1.157 | 2.037 | 1.934 |
Region growth (%)
| Region growth (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia YoY growth (%) | 222.7 | 40.2 | 10.1 |
United States YoY growth in A$ (%) | 67.3 | 54.2 | 6.6 |
Canada YoY growth (%) | 6,635 | 367.9 | -56.3 |
North America YoY growth (%) | 79.7 | 76.1 | -5.1 |
Region share of revenue (%)
| Region share of revenue (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Australia share (%) | 64.3 | 76.4 | 72.0 | 74.9 |
United States share (%) | 35.6 | 21.9 | 22.8 | 22.9 |
Canada share (%) | 0.1 | 1.7 | 5.2 | 2.2 |
Revenue History
| Period | Sales (AUD Mn) | YoY growth (%) | Source |
|---|---|---|---|
H1 FY2026 (Jul–Dec 2025) | 4.2 | 5 | Release 20 Jan 2026 |
Q2 FY2026 | 2.2 | — | Release 20 Jan 2026 (+11% QoQ) |
Q3 FY2026 | 1.5 | 16 | Q3 sales update (Apr 2026) |
Q4 FY2026 | 2.0 | 2 | Release 16 Jul 2026 |
H2 FY2026 | 3.5 | 7 | Release 16 Jul 2026 |
Valuation Snapshot
| Metric | Value | Date / source |
|---|---|---|
Nasdaq ADS price | US$1.76 | 9 Sep 2026 (MarketChameleon) |
Nasdaq ADS 52-week range | US$0.68 – US$2.39 | 2025–2026 (RedChip/Yahoo) |
ASX price | A$0.043 | 16 Jul 2026 (Kalkine) |
ASX price (indicative earlier points) | A$0.10 (Dec 2023/early 2024); A$0.041 (Jan 2026); A$0.027 (18 Mar 2026) | Google Finance snapshots |
Market capitalisation | ~US$14.2m | 9 Sep 2026 (MarketChameleon) |
1-year total return (ADS) | -6.4% | As of Sep 2026 (MarketChameleon) |
3-year and 5-year returns | — | Analyst observation from snapshots |
Beta | 1.38 | MarketChameleon (methodology not disclosed) |
Valuation Snapshot by Multiple
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation (AUD Mn) | 13.9 | 322.848m shares × A$0.043 |
Enterprise value (AUD Mn) | 4.9 | Market cap − cash A$9.02m (no debt; leases ignored) |
EV / Sales FY2026 (x) | 0.63 | EV / A$7.71m |
Price / Book FY2026 (x) | 1.26 | Market cap / equity A$11.0m |
Provider Details
| Provider | Rating | Target | Date | Note |
|---|---|---|---|---|
Emerging Growth Research | Buy-Extended | US$4.00 (raised from US$3.90) | 22 Apr 2026 | Methodology: peer EV/Revenue on TTM revenue adjusted for ADS; releases carried "SOURCE: Immuron Limited", suggesting company-distributed research |
Yahoo Finance 1-year target | — | US$3.92 | Mar 2026 | Aggregated |
Simply Wall St | — | — | Apr 2026 | States 2 covering analysts |
Capital Markets
| Item | Detail |
|---|---|
Dividend history | None paid or declared; no dividend policy beyond reinvestment |
Buybacks | Unmarketable-parcel buy-back (3,805,528 shares, A$121,777) June 2026; no general buy-back authorisation |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Debt maturity profile | No borrowings; lease liabilities A$30,606 current and A$158,937 non-current (30 June 2026) |
Equity facilities | F-3 shelf (July 2024, up to US$15m over three years); H.C. Wainwright ATM exhausted December 2025 |
Share Price & Returns
| Date | Shares issued | Price per ADS (USD) | Proceeds (AUD) |
|---|---|---|---|
8 Jan 2025 | 2,579,760 | 2.1784 | 226,567 |
15 Jan 2025 | 1,801,680 | 2.0971 | 152,300 |
29 May 2025 | 135,800 | 1.8435 | 9,744 |
3 Jun 2025 | 116,680 | 1.8286 | 8,216 |
17 Jul 2025 | 877,440 | 1.8939 | 63,351 |
18 Jul 2025 | 473,880 | 1.8782 | 34,072 |
21 Jul 2025 | 32,909,640 | 2.1374 | 2,711,754 |
20 Oct 2025 | 1,133,840 | 2.3008 | 100,458 |
7 Nov 2025 | 8,495,080 | 1.9631 | 642,228 |
5 Dec 2025 | 45,472,000 | 2.0809 | 3,596,835 |
Analyst Conclusions
Management guidance
No quantitative FY2027 guidance. Qualitative milestones (28 August 2026): Q1 FY2027 continued Travelan growth; Q2 portfolio expansion; Q3 IMM-529 partnering progress; Q4 geographic expansion, improved profitability and reduced cash burn. Investment in North American growth is planned. Consensus growth expectations: not available.
Bull case
-
Pipeline optionality is nearly free. With EV of roughly A$5m (~0.6x sales), any IMM-529 licence with a meaningful upfront payment relative to a ~US$14m market cap — against a US$400m peak-sales estimate and an IND already cleared — could re-rate the stock.
-
Commercial engine is re-accelerating at the margin. Q3 FY2026 growth of +16% and H2 FY2026 growth of +7% followed a weak H1; Canada's Q4 surge and the Jean Coutu listing suggest FY2027 Canada should grow strongly off a A$0.17m base, while Australia continues at ~10%.
-
Path to self-funding is visible. Operating burn halved to A$3.26m in FY2026; at 64.5% gross margin, roughly A$4.3m of incremental revenue at flat opex would close the FY2026 gap between gross profit and S&M plus G&A, and the A$9.0m cash balance provides multi-year runway at current burn.
Bear case
-
Clinical credibility of IMM-124E has been dented. The 866-participant USU field trial missed its primary endpoint; while confounded by third-party product and BID dosing, a partner must still fund a Phase 3 at TID dosing with limited field evidence — the 2024 CHIM showed only 36.4% efficacy.
-
Growth deceleration and margin erosion. Revenue growth fell from 171.7% to 48.6% to 5.9%; gross margin declined eight points since FY2023, and the business remains reliant on one brand and on a concentrated Australian pharmacy channel that has already destocked once.
-
Structural dilution and funding fragility. Shares outstanding rose 38% in FY2026, the ATM is exhausted, R&D tax incentive eligibility may end, and if partnering fails the company must either shelve the pipeline or raise again at depressed prices.
Catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| Mid-Oct 2026 | Q1 FY2027 sales update — tests "continued Travelan growth" milestone |
| Nov 2026 (expected) | 2026 AGM — board composition, remuneration votes, strategy update |
| Q2 FY2027 (Oct–Dec 2026) | "Portfolio expansion" — potential new in-licensed product or ProIBS NZ launch |
| Q3 FY2027 (Jan–Mar 2027) | IMM-529 partnering progress (Pullan process) |
| ~19 Feb 2027 (FactSet estimate) | H1 FY2027 results — burn rate under North American investment |
| Ongoing | FDA EOP2 meeting for IMM-124E (timing dependent on partner) |
| Ongoing | Australian R&D Tax Incentive legislation outcome |
| Ongoing | DoD/HJF program revenue and any expansion into a military-relevant multi-pathogen Travelan |
| Ongoing | Nasdaq ADS price relative to US$1 minimum bid; FPI rule changes |
Analyst verdict
Immuron has executed a credible turnaround of its commercial franchise since the COVID trough: Travelan revenue has grown roughly tenfold in four years, gross margins remain in the mid-60s, and the February 2026 Strategic Reset has reduced cash burn by nearly half while recapitalising the balance sheet to A$9.0m with no debt. The company met its own FY2026 guidance and exits the year with a fourth consecutive quarter of growth, an improving Canadian trajectory and a first non-dilutive revenue stream from the U.S. Department of Defense.
Yet the investment case remains finely balanced and highly binary. The operating business is still sub-scale — selling, marketing and corporate costs exceeded gross profit by A$2.8m in FY2026 — and organic growth has slowed to mid-single digits at group level, with single-brand and single-channel concentration. On the pipeline, the regulatory groundwork (two FDA INDs) is genuine, but the clinical evidence base for IMM-124E has weakened after the USU field study, and IMM-529 rests on compelling but purely pre-clinical data from 2017. Management's decision to partner both assets is financially rational but cedes most of the upside, and micro-cap biotechs often struggle to secure meaningful upfronts for Phase 2-ready anti-infective assets.
The current valuation — an enterprise value of roughly A$5m, about 0.6x trailing sales, with the pipeline effectively valued at zero — already discounts considerable failure. This creates asymmetric optionality: a signed IMM-529 licence or demonstrable progress toward EBITDA (ex-R&D) breakeven could drive a re-rating, while continued dilution or a stalled partnering process would likely extend the multi-year share-price decline. On balance, Immuron is a speculative, event-driven holding.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Notes |
|---|---|---|---|---|
Steven Lydeamore | Chief Executive Officer | Since 27 Jun 2022 | — | Named key person in 20-F; leads investor presentations |
Aaron Laurita | Chief Financial Officer | Since 9 Feb 2026 | Finance and commercial experience across several sectors (company release) | Replaced Phillip Hains |
Olga Smejkalova | Company Secretary | Since 9 Feb 2026 | Corporate governance and compliance experience (company release) | Signs SEC Form 6-K filings |
Dr Jerry Kanellos | Chief Scientific Officer | CSO per FY2026 20-F; appointed COO Nov 2020 (BusinessNews) | Long-serving scientific lead | Named key person in 20-F |
Phillip Hains (former) | CFO and Company Secretary | 2013 – 9 Feb 2026 | — | Resigned |
Board of Directors
| Name | Role | Appointed | Independence | Background | Age (third-party, date uncertain) |
|---|---|---|---|---|---|
Paul Brennan | Non-Executive Chairman | Director 16 Mar 2022; Chair from Jun 2023 | Independent (Investing.com) | CEO of PolyNovo Limited (ASX:PNV) 2015–2021; clinical background and multinational commercial experience | 62 |
Daniel Pollock | Non-Executive Director | 11 Oct 2012 | Independent (Investing.com) | Sole-practitioner commercial lawyer in Melbourne with international practice; seed investor/board member of small unlisted companies | 63 |
Ravi Savarirayan | Non-Executive Director | 7 Apr 2017 | Independent (Investing.com) | — | 56 |
Dr Jeannie (Jeannette) Joughin | Non-Executive Director | 1 Jun 2024 | Presumed independent | — | — |
“—” = not publicly disclosed.
Governance Detail
| Equity award (FY2026) | Recipients | Quantity | Exercise / conversion price (AUD) | Expiry | Grant-date fair value per unit (AUD) |
|---|---|---|---|---|---|
Non-executive director options (approved AGM 11 Nov 2025) | Joughin, Pollock, Savarirayan, Brennan — 1,000,000 each | 4,000,000 | 0.110 | 3 Oct 2029 | 0.0271 |
Employee performance rights (granted 16 Aug 2025) | Employees (KPI-based, vesting 1–5 years) | 2,147,154 | 0.145 | 16 Aug 2029 | 0.0640 |
Major Shareholders
| Holder category | Detail | Source |
|---|---|---|
U.S. institutional ADS holders (13F, Q2 2026) | Citadel Advisors added 29,319 ADS (≈US$31k); HRT Financial new position 20,584 ADS; Morgan Stanley, XTX, Two Sigma, Jane Street, Virtu reduced/exited | QuiverQuant 13F summary |
Historic insider example | Anastasiou family superfund held 2,494,746 shares (1.10%) — director since departed | Motley Fool AU (date uncertain) |
Insider trading | Daniel Pollock exercised 200,000 options at A$0.12 and sold 200,000 shares at A$0.157 (Mar 2024) | InvestSMART |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Product / approach | Relative positioning vs Immuron |
|---|---|---|---|
TD prevention — vaccines / Rx pipeline | Valneva (Nasdaq/Euronext: VALN) | Dukoral (oral cholera vaccine, some ETEC cross-protection in certain markets) | Established travel-vaccine franchise; Rx, not OTC |
TD prevention — pipeline | Scandinavian BioPharma | ETVAX oral ETEC vaccine | Clinical-stage; vaccine vs passive immunity |
TD prevention — pipeline | Eveliqure Biosciences | ETEC/Shigella vaccines | Named in Immuron 20-F |
TD prevention — pipeline | Lumen Bioscience | Oral spirulina-expressed antibodies (TD and CDI) | Most technologically similar; named in 20-F |
TD prevention — pipeline | Sigmoid Pharma; Intercell (now Valneva) | Named in Immuron 20-F | — |
TD OTC treatment / prevention | Kenvue (Imodium); Procter & Gamble (Pepto-Bismol) | Antidiarrhoeal / bismuth subsalicylate | Dominant brands; symptomatic treatment rather than antibody prophylaxis |
TD OTC — probiotics | Biocodex (Florastor/Saccharomyces boulardii) and pharmacy probiotics | Probiotic prophylaxis | Overlapping "travel gut" consumer need |
TD Rx | Bausch Health / Salix (rifaximin) | Antibiotic for TD treatment | Standard of care; antibiotic-resistance concerns favour non-antibiotic options |
CDI | Vedanta Biosciences | Defined bacterial consortium (VE303) | Named in 20-F |
CDI | Acurx Pharmaceuticals | Ibezapolstat (antibiotic) | Named in 20-F |
CDI | Ferring (Rebyota); Nestlé Health Science/Seres (Vowst) | Approved microbiome therapeutics for recurrent CDI | Approved products ahead of IMM-529 |
CDI | Crestone, BiomeBank, Deinove, LPOXY Therapeutics | Antibiotics / microbiome | Named in 20-F |
IBS (ProIBS) | Bayer (Iberogast); Opella/Sanofi (Buscopan); peppermint-oil and fibre products | OTC IBS symptom relief | ProIBS is a small new entrant |
Peer Comparison FY2026
| Company | Latest FY revenue | Revenue growth | Gross margin | R&D intensity | Note |
|---|---|---|---|---|---|
Immuron (FY2026, A$) | A$7.7m | 5.9% | 64.5% | 25.1% | Source: FY2026 4E |
Valneva (FY2024) | ~€170m total revenues | — | — | — | — |
Kenvue (FY2024) | ~US$15.5bn | — | — | — | — |
Bausch Health (FY2024) | ~US$9.6bn | — | — | — | — |
Recent Developments
--



